Cargando…

CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma

BACKGROUND: Patients suffering from squamous cell carcinoma of the larynx (LSCC) with lymphatic metastasis have a relatively poor prognosis and often require radical therapeutic management. The mechanisms which drive metastasis to the lymph nodes are largely unknown but may be promoted by a pro-angi...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlüter, Anke, Weller, Patrick, Kanaan, Oliver, Nel, Ivonne, Heusgen, Lukas, Höing, Benedikt, Haßkamp, Pia, Zander, Sebastian, Mandapathil, Magis, Dominas, Nina, Arnolds, Judith, Stuck, Boris A., Lang, Stephan, Bankfalvi, Agnes, Brandau, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845191/
https://www.ncbi.nlm.nih.gov/pubmed/29523110
http://dx.doi.org/10.1186/s12885-018-4180-5
_version_ 1783305376246005760
author Schlüter, Anke
Weller, Patrick
Kanaan, Oliver
Nel, Ivonne
Heusgen, Lukas
Höing, Benedikt
Haßkamp, Pia
Zander, Sebastian
Mandapathil, Magis
Dominas, Nina
Arnolds, Judith
Stuck, Boris A.
Lang, Stephan
Bankfalvi, Agnes
Brandau, Sven
author_facet Schlüter, Anke
Weller, Patrick
Kanaan, Oliver
Nel, Ivonne
Heusgen, Lukas
Höing, Benedikt
Haßkamp, Pia
Zander, Sebastian
Mandapathil, Magis
Dominas, Nina
Arnolds, Judith
Stuck, Boris A.
Lang, Stephan
Bankfalvi, Agnes
Brandau, Sven
author_sort Schlüter, Anke
collection PubMed
description BACKGROUND: Patients suffering from squamous cell carcinoma of the larynx (LSCC) with lymphatic metastasis have a relatively poor prognosis and often require radical therapeutic management. The mechanisms which drive metastasis to the lymph nodes are largely unknown but may be promoted by a pro-angiogenic tumor microenvironment. In this study, we examined whether the number of microvessels and the expression level of vascular endothelial growth factor (VEGF) in the primary tumor are correlated with the degree of lymph node metastasis (N-stage), tumor staging (T) and survival time in LSCC patients. METHODS: Tissue-Microarrays of 97 LSCC patients were analyzed using immunohistochemistry. The expression of VEGF was scored as intensity of staining (low vs high) and the number of CD31-positive vessels (median </≥7 vessels per visual field) was counted manually. Scores were correlated with N-stage, T-stage and 5-year overall survival rate. RESULTS: A high expression of angiogenic biomarkers was not associated with poor overall survival in the overall cohort of patients. Instead high CD31 count was associated with early stage cancer (p = 0.004) and in this subgroup high VEGF expression correlated with poor survival (p = 0.032). Additionally, in early stage cancer a high vessel count was associated with an increased recurrence rate (p = 0.004). CONCLUSION: Only in the early stage subgroup a high expression of angiogenic biomarkers was associated with reduced survival and an increased rate of recurrence. Thus, biomarkers of angiogenesis may be useful to identify high risk patients specifically in early stage LSCC.
format Online
Article
Text
id pubmed-5845191
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58451912018-03-14 CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma Schlüter, Anke Weller, Patrick Kanaan, Oliver Nel, Ivonne Heusgen, Lukas Höing, Benedikt Haßkamp, Pia Zander, Sebastian Mandapathil, Magis Dominas, Nina Arnolds, Judith Stuck, Boris A. Lang, Stephan Bankfalvi, Agnes Brandau, Sven BMC Cancer Research Article BACKGROUND: Patients suffering from squamous cell carcinoma of the larynx (LSCC) with lymphatic metastasis have a relatively poor prognosis and often require radical therapeutic management. The mechanisms which drive metastasis to the lymph nodes are largely unknown but may be promoted by a pro-angiogenic tumor microenvironment. In this study, we examined whether the number of microvessels and the expression level of vascular endothelial growth factor (VEGF) in the primary tumor are correlated with the degree of lymph node metastasis (N-stage), tumor staging (T) and survival time in LSCC patients. METHODS: Tissue-Microarrays of 97 LSCC patients were analyzed using immunohistochemistry. The expression of VEGF was scored as intensity of staining (low vs high) and the number of CD31-positive vessels (median </≥7 vessels per visual field) was counted manually. Scores were correlated with N-stage, T-stage and 5-year overall survival rate. RESULTS: A high expression of angiogenic biomarkers was not associated with poor overall survival in the overall cohort of patients. Instead high CD31 count was associated with early stage cancer (p = 0.004) and in this subgroup high VEGF expression correlated with poor survival (p = 0.032). Additionally, in early stage cancer a high vessel count was associated with an increased recurrence rate (p = 0.004). CONCLUSION: Only in the early stage subgroup a high expression of angiogenic biomarkers was associated with reduced survival and an increased rate of recurrence. Thus, biomarkers of angiogenesis may be useful to identify high risk patients specifically in early stage LSCC. BioMed Central 2018-03-09 /pmc/articles/PMC5845191/ /pubmed/29523110 http://dx.doi.org/10.1186/s12885-018-4180-5 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Schlüter, Anke
Weller, Patrick
Kanaan, Oliver
Nel, Ivonne
Heusgen, Lukas
Höing, Benedikt
Haßkamp, Pia
Zander, Sebastian
Mandapathil, Magis
Dominas, Nina
Arnolds, Judith
Stuck, Boris A.
Lang, Stephan
Bankfalvi, Agnes
Brandau, Sven
CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma
title CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma
title_full CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma
title_fullStr CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma
title_full_unstemmed CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma
title_short CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma
title_sort cd31 and vegf are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845191/
https://www.ncbi.nlm.nih.gov/pubmed/29523110
http://dx.doi.org/10.1186/s12885-018-4180-5
work_keys_str_mv AT schluteranke cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma
AT wellerpatrick cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma
AT kanaanoliver cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma
AT nelivonne cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma
AT heusgenlukas cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma
AT hoingbenedikt cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma
AT haßkamppia cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma
AT zandersebastian cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma
AT mandapathilmagis cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma
AT dominasnina cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma
AT arnoldsjudith cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma
AT stuckborisa cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma
AT langstephan cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma
AT bankfalviagnes cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma
AT brandausven cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma